Inhibition of Olig2 activity

A compound having the structure of Formula (I):

• wherein:
• is
• wherein
• is unsubstituted or substituted by 1, 2 or 3 R1 groups;
• each R1 is independently halogen, —CN, —NO2, —OH, —OCF3, —OCH2F, —OCF2H, —CF3, —SR8, —N(R8)S(═O)2R9, —S(═O)2N(R8)2, —S(═O)2R9, —S(═O)2R9, —C(═O)R9, —CO2R8, —N(R8)2, —C(═O)N(R8)2, or —N(R8)C(═O)R9;
• R2 and R3 are each independently H, or C1-C4alkyl;
• R4 and R5 are independently H, halogen, —CN, —OH, —CF3, or;
• R6 is H, unsubstituted C1-C6 haloalkyl,
• (C(R14)(R15))mN(R11)(R12), —(C(R14)(R15))mOR13, or —OR22;
• each R8 is independently H or C1-C6alkyl;
• each R9 is independently C1-C6alkyl;
• R10 is H or C1-C4alkyl;
• R11 is H, or C1-C6alkyl;
• R12 is H or C1-C6 alkyl;
• R13 is H or C1-C6alkyl;
• each R14 and R15 is each independently H, halogen, or C1-C6alkyl;
• R22 is H, or C1-C6alkyl;
• m is 2-6;
• and
• n is 1-5;
• or
• a pharmaceutically acceptable salt thereof.